The fold‐change in cTnT levels of the tofersen‐cohort (median 1.2; IQR 0.77–1.59) was significantly less compared to the control ALS patients (median 1.89; IQR 1.35–2.75) (p = 0.0003). This evidence concerns the gene TNNT2 and amyotrophic lateral sclerosis.